Moors & Cabot’s Vera Therapeutics VERA Stock Holding History

Moors & Cabot’s Portfolio VERA Stock Details VERA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-5,200	Closed	-$220K	–	927
2024 Q4	$220K	Buy	+5,200	New	+$230K	0.01%	778

Other funds holding VERA

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return

Moors & Cabot's VERA Position: Q1 2025 in Review

Moors & Cabot sold out of Vera Therapeutics (VERA) in Q1 2025, closing a stake of 5,200 shares — an estimated $220K sold.

Moors & Cabot first reported a position in VERA in Q4 2024 and held it in 1 quarter. The position peaked at $220K in Q4 2024. 179 funds tracked by Wall St. Rank hold VERA as of Q1 2025.

Moors & Cabot reported no remaining Vera Therapeutics position as of Q1 2025 after selling out during the quarter.
Moors & Cabot sold 5,200 Vera Therapeutics shares in Q1 2025, an estimated $220K.
Moors & Cabot first reported a position in Vera Therapeutics in Q4 2024 and held it in 1 quarter.
Moors & Cabot's Vera Therapeutics position peaked at $220K in Q4 2024.
179 funds tracked by Wall St. Rank held Vera Therapeutics as of Q1 2025.

Based on Moors & Cabot's 13F filing for Q1 2025, filed 8 May 2025.